Moreover, we identified that EREG expression has the potential to serve as a biomarker to predict response to erlotinib treatment and to stratify HNSCC patients, particularly those with EREGhigh-EGFR+ disease. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.